NCT07023965View on ClinicalTrials.gov

Follow-up Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-L)

Enrolling by invitationOBSERVATIONAL
Enrollment

542

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Peripheral Arterial Disease(PAD)Arterial Occlusive DiseaseArteriosclerosis ObliteransThromboangiitis ObliteransDiabetic Foot Ulcer (DFU)Diabetic Foot Ulcer IschemicCritical Limb Ischemia (CLI)
Interventions
DRUG

NL003

This is an observational study, and the interventions have already been administered in the preceding Phase III clinical trials.

DRUG

Placebo

This is an observational study, and the interventions have already been administered in the preceding Phase III clinical trials.

Trial Locations (5)

100032

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing

024000

Chifeng Municipal Hospital, Chifeng

Unknown

zhongshan Hospital Affiliated of Dalian University, Dalian

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

The First Affiliated Hospital of Xi 'an Jiaotong University, Xi'an

All Listed Sponsors
lead

Beijing Northland Biotech. Co., Ltd.

INDUSTRY